Biotechnology - Alexion Pharmaceuticals

Filter

Current filters:

Alexion Pharmaceuticals

Popular Filters

28 to 52 of 2119 results

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

Pharma is attracted to early-stage antibody deals in oncology

02-04-2014

Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching…

BiotechnologyLicensingOncology

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Amarin and Kowa Pharma to co-promote Vascepa in USA

01-04-2014

US biotech firm Amarin Corp and Kowa Pharmaceuticals America, owned by Japan’s Kowa, have reached an…

AmarinBiotechnologyCardio-vascularKowa PharmaceuticalsMarkets & MarketingNorth AmericaUSAVascepa

Paul Sekhri joins Sanofi as Senior Vice President

Paul Sekhri joins Sanofi as Senior Vice President

01-04-2014

Paul Sekhri has joined French drug major Sanofi as Senior Vice President, Integrated Care effective…

BiotechnologyBoardroomPharmaceuticalSanofiUSA

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

SOBI assumes direct responsibility for rare disease drug Orfadin in the USA and Canada

SOBI assumes direct responsibility for rare disease drug Orfadin in the USA and Canada

01-04-2014

Biotech firm Swedish Orphan Biovitrum has assumed direct responsibility for the distribution of its proprietary…

BiotechnologyMarkets & MarketingNorthern EuropeOrfadinRare diseasesSobi

Fairjourney Biologics signs agreement to develop therapeutic antibodies for heparanase

01-04-2014

Portuguese antibody solutions company Fairjourney Biologics has signed a research and option agreement…

BiotechnologyOncologyPortugalResearch

Tiziana Pharma plans listing via reverse takeover

Tiziana Pharma plans listing via reverse takeover

31-03-2014

Tiziana Pharma, a recently-established UK biotech company that has licensed technology for a potential…

BiotechnologyMergers & AcquisitionsOncologyTiziana

Convergence Pharma and Evotec collaborate on chronic pain drugs

Convergence Pharma and Evotec collaborate on chronic pain drugs

31-03-2014

Independent UK biotech firm Convergence Pharmaceuticals has entered into a research alliance with Germany’s…

BiotechnologyConvergence PharmaceuticalsEvotecNeurologicalResearch

Sanofi appoints Dr Anne Beal as chief patient officer

Sanofi appoints Dr Anne Beal as chief patient officer

31-03-2014

French drug major Sanofi has announced the appointment of Anne Beal to the newly created position of…

BiotechnologyBoardroomFrancePharmaceuticalSanofiUSA

aTyr Pharma appoints David Weiner as Chief Medical Officer

aTyr Pharma appoints David Weiner as Chief Medical Officer

31-03-2014

aTyr Pharma, a rare disease biotherapeutics enterprise, has announced the appointment of David Weiner…

aTyrBiotechnologyBoardroomUSA

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

European biotech RDI incentives need to ensure greater economic growth

European biotech RDI incentives need to ensure greater economic growth

28-03-2014

European governments must remain committed to biotech research, development and innovation (RDI) incentives…

BiotechnologyEuropeFinancialPoliticsResearch

Robust 2013 for biotech licensing deals; average up-front payment jump 60%

28-03-2014

Biotech licensing deals have been trending up markedly in recent months, according to the new installment…

BiotechnologyFinancialLicensing

Australian government plans no action on Pharmaceutical Patent Review

Australian government plans no action on Pharmaceutical Patent Review

27-03-2014

The Australian federal government last week released a statement on the Pharmaceutical Patent Review…

Asia-PacificAustraliaBiotechnologyPatentsResearch

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

27-03-2014

Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

Proposed new bill would create new patent term extension for certain biologics patents in USA

Proposed new bill would create new patent term extension for certain biologics patents in USA

26-03-2014

Earlier this week in the USA, legislation was introduced allowing new sponsors to gain intellectual property…

BiotechnologyLegalNorth AmericaPatentsPoliticsUSA

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

28 to 52 of 2119 results

Company Spotlight

Fibrotech

Fibrotech

Back to top